Nvidia-backed Recursion Pharmaceuticals falls on bigger-than-expected Q4 loss

Recursion Pharmaceuticals

28/02/2025 14:41

** Shares of Nvidia-backed AI drug developer Recursion Pharmaceuticals RXRX.O fall 13% to $6.67 premarket

** The company posts Q4 revenue of $4.5 million, missing analysts' estimate of $19 million, according to data compiled by LSEG

** Reports Q4 net loss of 53 cents per share versus a loss estimate of 43 cents per share

** Recursion wants to be the Amazon Prime of pharma by adopting a subscription model for selling its pipeline of medicines, Bloomberg reports

** The company files for stock offering of up to $500 million - filing

** It has ~390 mln outstanding shares, with a market capitalization of $3 bln, according to data compiled by LSEG

** RXRX has fallen ~51% in the last 12 months

 (Reporting by Siddhi Mahatole)

 ((Siddhi.mahatole@thomsonreuters.com))